

14 August 2017



*Improving the quality of life for people in pain through novel,
cost effective pain assessment tools*

ePAT Technologies Limited
ABN 21 146 035 127

Suite 401, 35 Lime Street, Sydney, NSW, 2000
Registered Office: Suite 5, 95 Hay Street Subiaco WA 6008
Phone +61 8 9388 8290

Mr Rupa Kapadia
Adviser – Listings Compliance
ASX Compliance Pty Ltd
20 Bridge Street
SYDNEY NSW 2000

Dear Sir

PRICE QUERY

We refer to your letter dated 14 August 2017.

1. Is ePAT aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities

Response: No

2. If the answer to question 1 is “yes”:

Response: N/A

3. Is there any other explanation that ePAT may have for the recent trading in its securities?

Response: ePAT has announced several key milestones in recent months regarding commercialization of the Company’s technology.

On 19 July 2017, ePAT announced:

- ePAT App is now cleared for use as a medical device in Australia (TGA) and CE marked for European markets
- Regulatory clearance is a key business milestone and requirement by the ePAT customer base
- Australian Commercialisation of the ePAT App remains on schedule for Q4 2017 and Europe during 2018

On 24 July 2017, ePAT announced:

- ePAT has reached a key agreement with nViso for a perpetual, exclusive, global license to use nViso Artificial Intelligence (AI) technology for pain assessment in healthcare

- ePAT welcomes new strategic investor to the share register, nViso* who are recognised internationally for their expertise in artificial intelligence and micro expression analysis
 - Partnership between the two parties will accelerate the development and commercialisation of AI in innovative mobile applications
 - Payment to nViso will be shares and cash, aligning the parties to commercialisation success
4. Please confirm ePAT is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.

Response: Confirmed

5. Please confirm that ePAT's responses to the questions above have been authorized and approved

Response: Confirmed

Yours sincerely



Ian Hobson
Company Secretary



14 August 2017

Mr Ian Hobson
Company Secretary
ePAT Technologies Limited
Suite 5, 95 Hay Street
Subiaco WA 6008

By email: ianhobson@bigpond.com

Dear Mr Hobson,

ePAT Technologies Limited ("ePAT"): Price query

We note the change in the price of ePAT's securities from a close of \$0.039 on Tuesday 8 August 2017 to a high of \$0.056 today at the time of writing.

In light of this, ASX asks ePAT to respond separately to each of the following questions and requests for information:

1. Is ePAT aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?
2. If the answer to question 1 is "yes":
 - a) Is ePAT relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1?

Please note that the recent trading in ePAT's securities would suggest to ASX that such information may have ceased to be confidential and therefore ePAT may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.
 - b) Can an announcement be made immediately?

Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).
 - c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?
3. If the answer to question 1 is "no", is there any other explanation that ePAT may have for the recent trading in its securities?
4. Please confirm that ePAT is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.
5. Please confirm that ePAT's responses to the questions above have been authorised and approved in accordance with its published continuous disclosure policy or otherwise by its board or an officer of ePAT with delegated authority from the board to respond to ASX on disclosure matters.

When and where to send your response

This request is made under, and in accordance with, Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by not later than 4:00 pm AEST on Monday 14 August 2017. If we do not have your response by then, ASX will have no choice but to consider suspending trading in ePAT's securities under Listing Rule 17.3.

You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A ePAT's obligation is to disclose the information "immediately". This may require the information to be disclosed before the deadline set out in the previous paragraph.

ASX reserves the right to release a copy of this letter and your response on the ASX Market Announcements Platform under Listing Rule 18.7A. Accordingly, your response should be in a form suitable for release to the market.

Your response should be sent to me by e-mail at rupa.kapadia@asx.com.au. It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

Listing Rules 3.1 and 3.1A

Listing Rule 3.1 requires a listed entity to give ASX immediately any information concerning it that a reasonable person would expect to have a material effect on the price or value of the entity's securities. Exceptions to this requirement are set out in Listing Rule 3.1A.

In responding to this letter, you should have regard to ePAT's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure: Listing Rules 3.1 – 3.1B*.

It should be noted that ePAT's obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

Trading halt

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is "yes" and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in ePAT's securities under Listing Rule 17.1.

If you wish a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.

We may require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted.

You can find further information about trading halts in Guidance Note 16 *Trading Halts & Voluntary Suspensions*.

If you have any queries or concerns about any of the above, please contact me immediately.

Yours sincerely

[Sent electronically without signature]

Rupa Kapadia
Listings Adviser

P: (02) 92270932

E: rupa.kapadia@asx.com.au